Cambridge Commercial Property Market 2026.

This is the working broker read on the Cambridge commercial property market at mid-2026. We have written it for owner-occupiers thinking about buying their premises, investors holding or refinancing lab, office or mixed-use stock, life sciences operators looking at freehold acquisition on the science park ring, and HMO and semi-commercial investors holding through the central student belts. The aim is practical: what is happening in each part of the market, where lender appetite sits in 2026, what the rate range is across each product, and how we read the Cambridge pipeline through to the end of 2027. The voice is first-person plural because we sit across deals every week, not because we are pretending to speak for anyone else. Where we name a lender, it is one of the eight on our active panel that we quote against routinely on Cambridge deals, with the wider ninety-strong network sitting behind that for the specialist and life sciences cases.

Cambridge is a small city in headcount terms and a global city in economic terms. The population inside the city boundary sits at around 145,000, with the wider metro reach across the immediate South Cambridgeshire flank closer to 290,000. The city is a unitary district inside the ceremonial county of Cambridgeshire, with Greater Cambridge Shared Planning running the planning function jointly between Cambridge City Council and South Cambridgeshire District Council. That joint planning arrangement matters for brokers because it means a single planning pipeline view across the city and the major science park ring, including Cambridge Biomedical Campus, Cambridge Science Park, Granta Park and Babraham Research Campus.

The economy is anchored by three structural pillars. Life sciences and biotech run through the Cambridge Biomedical Campus at Addenbrooke's, the AstraZeneca Discovery Centre, the wider Cambridge Science Park occupier base and the Granta Park and Babraham research clusters. Information technology and deep tech sits across Cambridge Science Park, St John's Innovation Park, the West Cambridge site and a wider scattering of ARM, Microsoft Research, Apple Cambridge and Toshiba research footprints. Higher education carries the University of Cambridge at around 24,000 students and Anglia Ruskin at around 30,000, anchoring unusually deep central retail, hospitality, leisure, HMO and semi-commercial demand. Professional services along Hills Road, St Andrew's Street and the Station Road triangle pick up the legal, accountancy and surveying functions servicing all three pillars.

The transport spine is fundamental to how the commercial market trades. Cambridge sits 50 minutes by train from London King's Cross on the East Coast Main Line via the Cambridge Main station, with a parallel Liverpool Street service via Cambridge North. Cambridge North station, opened in 2017, sits next to Cambridge Science Park and St John's Innovation Park, materially shortening the commute to the major northern employment cluster. Cambridge South station, serving the Cambridge Biomedical Campus directly, sits inside the watching brief through late 2026 and 2027. When it opens, it will be the first new mainline station in the city in a generation and will reset rent and yield positions for the CBC, Hills Road and Trumpington commercial flank. The A14 and M11 anchor the road network, with the A14 connecting Cambridge west to the Midlands and east through Newmarket and Bury St Edmunds, and the M11 running south to London and the Stansted catchment.

The life sciences spine is the defining Cambridge commercial story. The cluster runs across six flagship locations within a 12-mile radius of the city centre, anchored by global pharma, biotech and research institute occupiers. The Cambridge Biomedical Campus at Addenbrooke's in CB2 is the largest single site, combining Cambridge University Hospitals NHS Foundation Trust, the AstraZeneca Discovery Centre, the MRC Laboratory of Molecular Biology, the Cancer Research UK Cambridge Institute and a wider set of research and clinical buildings. The campus sits south of the city centre adjacent to the Trumpington flank and the forthcoming Cambridge South station. Floor plates here run from 5,000 sq ft of incubator space inside the Bio Innovation Centre up to the larger AstraZeneca research buildings. Prime fitted lab rents on the CBC sit at the top end of the city range, £60 to £75 psf for category-2 specification, with shell-and-core pricing meaningfully lower depending on the fit-out contribution structure.

Cambridge Science Park in CB4, the longest-established science park in the UK, was founded by Trinity College in 1970 and runs around 152 acres north of the city centre adjacent to Cambridge North station. The occupier base is unusually deep: AstraZeneca diagnostics, Abcam (now part of Danaher), Domino Printing, ARM, Microsoft Research and a long tail of earlier-stage biotech and tech occupiers. The park trades a wide range of office, lab and hybrid floor plates from 3,000 sq ft up to 100,000 sq ft. Office rents on the park sit at 32 to 45 pounds psf in 2026, lab fit-out at 50 to 65 on the most recent specifications. Investment yields on long-let single-occupier lab buildings have traded at 5.5 to 6.5% net through the past two years, materially inside comparable business park stock elsewhere.

Granta Park sits 10 miles south of the city centre at Great Abington, anchored by AstraZeneca, Pfizer research, Gilead Sciences and the Wellcome Sanger Institute's wider partner footprint. The occupier base skews toward large covenant operators on long unexpired terms. Babraham Research Campus in CB22 carries the BBSRC institute alongside a bioincubator and venture-backed biotech start-ups. Both Granta and Babraham trade investment volumes through EG-listed deals at yields broadly inside the Cambridge Science Park range. The publicly available data is thinner because both schemes trade through paywalled investment listings, but lender appetite on owner-occupier acquisition for life sciences operators with credible covenants is consistently open.

St John's Innovation Park in CB4, owned by St John's College, anchors the earlier-stage and scale-up biotech and tech occupier base immediately east of Cambridge Science Park. The park trades floor plates from 1,000 sq ft to 30,000 sq ft, with a managed-workspace heritage that runs deep into the Cambridge ecosystem. Cambridge Research Park in CB25 sits further north at Waterbeach, with a larger and lower-cost footprint suited to operators needing scale-up manufacturing or warehousing alongside R&D. Melbourn Science Park on the South Cambridgeshire boundary at CB22 picks up similar shapes at the southern end. These secondary parks run office and lab rents 10 to 20 percent inside the headline CBC and CSP numbers, which matters for owner-occupier biotech operators looking to anchor their first freehold acquisition.

Investor appetite for Cambridge lab and life sciences product has been one of the strongest themes of the last two years. UK and US institutional capital, specialist life sciences REITs and private credit sleeves have all bid into the Cambridge cluster, pricing investment cap rates inside the wider UK prime office market by a clear margin. The owner-occupier wave runs alongside that: maturing biotech businesses that have outgrown their incubator space buy their first freehold building, typically in the 8,000 to 30,000 sq ft range, with five-year trading runways and venture-backed balance sheets. The combination of long-covenant tenant occupier demand and scale-up freehold acquisition keeps the market liquid through cycles that would freeze comparable assets elsewhere.

Lender stance on Cambridge lab and life sciences finance is positioned as follows. Stabilised investment with strong unexpired and credible covenants sits with the clearing-bank corporate desks: Lloyds, NatWest, Barclays and Santander all carry life sciences appetite into the 5 million to 50 million pound lot size band. Owner-occupier life sciences freehold for earlier-stage operators with venture funding but limited trading history is the more nuanced piece: the clearing banks underwrite on cash runway and shareholder covenant, with Shawbrook, InterBay Commercial and Cynergy Bank stepping in where the trading history is thinner. Cambridge & Counties Bank, the Cambridge-headquartered specialist challenger, sits on the wider panel for SME owner-occupier and investment cases on the science-park ring and the central professional services flank, with its local-market expertise on Cambridge stock the differentiator.

Commercial mortgage product across Cambridge runs between 6.0 and 9.0% pa at mid-2026, depending on sector, covenant, LTV and term. Owner-occupier professional services and healthcare freehold along Hills Road, St Andrew's Street and the central Cambridge professional belt sits at the strongest end of the range, 6.0 to 7.5% pa at 65 to 75% LTV on five to fifteen-year fixed-amortisation terms. Owner-occupier life sciences freehold on the science park ring runs similar pricing where the borrower has credible trading accounts and venture or corporate covenant context, 6.5 to 7.5% pa at 65 to 70% LTV. Investment commercial mortgages on stabilised lab and life sciences product with strong unexpired sit at 6.5 to 7.5% pa at 60 to 70% LTV on the cleanest cases.

Semi-commercial mixed-use on Mill Road, Romsey, Petersfield and the Chesterton parade runs up to 75% LTV at 7.0 to 8.0% pa across the strong shop-with-flat archetype. HMO acquisition or refinance on larger central residential blocks converted to professional sharers runs 7.5 to 8.5% pa at 70 to 75% LTV with the specialist HMO desks. Trading-business commercial mortgages on hospitality, wedding venues, late-night bars and the central King's Parade pub and restaurant trade are the toughest segment: typically 8.0 to 9.0% pa, sub 65% LTV, with Shawbrook, InterBay Commercial and Cynergy Bank more open than the clearers on cases with two to three years of clean trading accounts. Bridging across the catchment sits at 0.75 to 1.10% per month on the mainstream specialist desks, with the cleanest cases on lower-LTV change-of-use and refurb-to-term plays pricing toward the lower end.

Lender appetite splits by sector. Lab and life sciences product is the most contested asset class in Cambridge, with both clearing-bank corporate desks and specialist life sciences lenders bidding into stabilised investment cases. The clearing banks at Lloyds, NatWest, Barclays and Santander all carry credible Cambridge appetite into the prime science park and central professional services flank. The challenger SME panel writes the bulk of the mid-market: Shawbrook, InterBay Commercial, LendInvest and Cynergy Bank sit at the centre of the specialist pool, with Cambridge & Counties Bank as the Cambridge-headquartered specialist on the wider panel adding local-market expertise on SME owner-occupier, semi-commercial and portfolio cases. The wider ninety-strong panel rounds out the appetite across challenger banks, specialists and private credit on the more complex cases.

We are part of a broader UK commercial mortgage brokerage network. For the wider regional view across Cambridgeshire, taking in South Cambridgeshire, East Cambridgeshire, Huntingdonshire, Fenland and Peterborough alongside the Cambridge catchment, see our Cambridgeshire commercial mortgage broker hub, which sets out the parent brokerage's Cambridge desk and the panel coverage across the wider Cambridgeshire and East Anglia footprint.

Five anonymised composite deal flavours, each drawn from the recurring shapes we see across Cambridge. Names removed, terms representative of the range we are pricing through Q1 and Q2 2026.

Cambridge Science Park lab investment refinance. An investor holding a 14,000 sq ft single-let lab building on the Cambridge Science Park flank, refinancing off a 2021 five-year fix into a stabilised five-year investment facility with Lloyds. Twelve years unexpired to a mid-stage biotech operator with venture backing. 60% LTV at 7.20% pa, 25-year amortisation. The cluster covenant context supported clearing-bank pricing inside what the specialist pool was quoting.

Hills Road professional services owner-occupier. A solicitor partnership buying a 4,200 sq ft Edwardian Hills Road townhouse from a retiring partner group, three years clean accounts, combined freehold and partnership facility through NatWest. 70% LTV at 6.95% pa, five-year fix, 15-year term. The Hills Road professional services freehold archetype is one of the cleanest shapes we price.

Mill Road semi-commercial portfolio refinance. A private investor with five Mill Road and Romsey shop-with-flats consolidating four short-dated facilities onto a single commercial portfolio loan with Shawbrook. 70% LTV at 7.40% pa, five-year fix, 25-year amortisation. Stabilised mixed Class E ground floor and assured shorthold residential income above, with blended ICR around 150 percent supporting the upper LTV.

Newmarket Road hotel acquisition. A regional hotel operator acquiring a 60-room mid-market branded hotel on the Newmarket Road cluster, four years of clean trading accounts at the existing operating brand, EBITDA cover comfortably above 1.5 times. 65% LTV at 7.85% pa, five-year fix through InterBay Commercial, 20-year amortisation. The branded operating context and the trading-business track record supported the specialist underwrite at the upper LTV for hotel product.

Petersfield HMO conversion. An investor acquiring a large central Petersfield Victorian house under HMO use, converted to seven en-suite professional sharer rooms targeting the post-doctoral and early-career researcher base working at CBC. 70% LTV at 7.65% pa with LendInvest, five-year fix, 25-year amortisation. Cambridge HMO yields on professional sharer stock remain among the strongest in the UK, and the lender stance reflects that.